You are here

Markers of inflammation in prevalent and incident Parkinson's disease in the Cardiovascular Health Study.

TitleMarkers of inflammation in prevalent and incident Parkinson's disease in the Cardiovascular Health Study.
Publication TypeJournal Article
Year of Publication2012
AuthorsTon, TGN, Jain, S, Biggs, ML, Thacker, EL, Strotmeyer, ES, Boudreau, R, Newman, AB, Longstreth, WT, Checkoway, H
JournalParkinsonism Relat Disord
Volume18
Issue3
Pagination274-8
Date Published2012 Mar
ISSN1873-5126
KeywordsAged, Aged, 80 and over, Albumins, Biomarkers, C-Reactive Protein, Enzyme-Linked Immunosorbent Assay, Female, Fibrinogen, Humans, Incidence, Inflammation, Interleukin-6, Leukocyte Count, Male, Parkinson Disease, Prevalence, Risk Factors, Tumor Necrosis Factor-alpha
Abstract<p><b>BACKGROUND: </b>Studies demonstrate existence of inflammation in prevalent Parkinson's disease (PD). We assessed associations of baseline levels of inflammatory markers with prevalent PD at baseline (1989) and incident PD identified over 13 years of follow-up of the Cardiovascular Health Study.</p><p><b>METHODS: </b>Blood samples at baseline were measured for fibrinogen, interleukin-6, tumor necrosis factor-α, C-reactive protein, albumin, and white blood cells. The analysis included 60 prevalent and 154 incident PD cases.</p><p><b>RESULTS: </b>Risk of prevalent PD was significantly higher per doubling of IL-6 among women (odds ratio [OR]=1.5, 95% confidence interval [CI]: 1.0, 2.4) and WBC among men (OR: 2.4, 95% CI: 1.2, 4.9) in multivariate models. Risk of incident PD was not associated with higher levels of any biomarker after adjusting for age, smoking, African American race, and history of diabetes. Inverse associations with incident PD were observed per doubling of C-reactive protein (OR=0.9; 95% CI: 0.8, 1.0) and of fibrinogen among women (OR=0.4; 95% CI: 0.2, 0.8).</p><p><b>CONCLUSIONS: </b>Although inflammation exists in PD, it may not represent an etiologic factor. Our findings suggest the need for larger studies that measure inflammatory markers before PD onset.</p>
DOI10.1016/j.parkreldis.2011.11.003
Alternate JournalParkinsonism Relat. Disord.
PubMed ID22119505
PubMed Central IDPMC3288759
Grant ListT32 HL007902 / HL / NHLBI NIH HHS / United States
N01 HC085086 / HC / NHLBI NIH HHS / United States
P30 AG024827 / AG / NIA NIH HHS / United States
UL1 TR000005 / TR / NCATS NIH HHS / United States
R01 AG015928-02 / AG / NIA NIH HHS / United States
P30 AG024827-01 / AG / NIA NIH HHS / United States
R01 AG015928 / AG / NIA NIH HHS / United States
U01 HL080295 / HL / NHLBI NIH HHS / United States
N01 HC075150 / HC / NHLBI NIH HHS / United States
KL2 RR024154-01 / RR / NCRR NIH HHS / United States
U01 HL080295-01 / HL / NHLBI NIH HHS / United States
KL2 RR024154 / RR / NCRR NIH HHS / United States
N01HC55222 / HL / NHLBI NIH HHS / United States
R03 NS057257-02 / NS / NINDS NIH HHS / United States
K23 NS070867 / NS / NINDS NIH HHS / United States
R03 NS057257 / NS / NINDS NIH HHS / United States
R03 NS057257-01A2 / NS / NINDS NIH HHS / United States
KL2 TR000146 / TR / NCATS NIH HHS / United States
T32 HL007902-01 / HL / NHLBI NIH HHS / United States
N01HC85079 / HL / NHLBI NIH HHS / United States
N01 HC045133 / HC / NHLBI NIH HHS / United States
N01 HC035129 / HC / NHLBI NIH HHS / United States